Indian Dental Consumables Market Expected to Reach $232,527 Thousand by 2023

 

Indian Dental Consumables Market was valued at $116,397 thousand in 2016, and is projected to reach $232,527 thousand by 2023, registering a CAGR of 10.3% from 2017 to 2023. The other consumables segment dominated the consumables market, accounting for a share of more half of the market in 2016.

 

Dental consumables include medical devices such as dental sundries, small equipment, dental restoration devices, and other consumables to treat dental caries and periodontal diseases.

 

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/2383

 

The growth of the Indian dental consumables market is driven by rise in investments for establishment of multispecialty hospitals offering dentistry, increased efforts to establish India as a manufacturing hub for dental supplies, and growth in in dental tourism due to low cost and efficient treatment. However, price sensitivity of the dental consumables due to fluctuating currency exchange rates is expected to limit the market growth. Increased focus of the multinationals such as Dentsply Sirona, 3M, and others to invest and expand in India is expected to offer lucrative opportunity for the market.

 

The endodontics segment is expected to register highest CAGR of 12.6% from 2017 to 2023, owing to increase in prevalence of dental problems among all age groups.

 

Key Findings of the Indian Dental Consumables Market:

• The dental ceramics segment is projected to grow at CAGR of 11.6% during the forecast period.
• The top five metro cities dominated the market in 2016, accounting for five-sixths share of the market.
• In 2016, the handheld RC files segment accounted for a share of more than half of the total Indian dental consumables market.
• The dental disposables segment accounted for the highest CAGR of 12.2% in 2016.

 

 For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2383

 

In 2016, top five metro cities accounted for a share of five-sixths of the Indian market, owing to increase in prevalence of various dental problems such as periodontal diseases and dental caries. Next 40 towns holds the second position in the Indian dental consumables market.

 

The major companies profiled in the report include 3M Company, Anand Meproducts Pvt. Ltd., Danaher Corporation, Dentsply Sirona, Indident, Institut Straumann AG, Mil Medical Dental Systems Pvt. Ltd., Osstem Implant Co. Ltd., Prime Dental Products Pvt. Ltd., Zimmer Biomet, and Mani Inc.

Insomnia Market Expected to Reach $5,488 Million by 2023

 

Insomnia Market accounted for $4,093 million in 2016, and is estimated to reach $5,488 million by 2023, registering a CAGR of 4.2% from 2017 to 2023. North America was the highest contributor in the insomnia market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.

 

Insomnia is a sleep disorder where in people have problem in falling asleep or remaining asleep. The major causes of insomnia include high stress level, mental disorders, excessive consumptions of caffeine & alcohol, and other medical conditions. Insomnia is categorized into three types depending on the duration of the disorder, namely transient (few days), acute (few weeks), and chronic insomnia (few months or even years).

 

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/2373

 

The global insomnia market is driven by factors such as emergence of therapeutics with fewer side-effects and rise in demand for over-the-counter (OTC) sleep aids. Few drugs that are used for the treatment of chronic diseases affect the quality of sleep; thereby, increasing the number of insomnia cases. Furthermore, rise in geriatric population and growth in disposable income are expected to boost the market growth. However, the side-effects caused due to excessive use of sleep medication and patent expiration of many prescription drugs are expected to hamper the market growth.

 

The pharmacological therapy segment is the highest contributor to the market growth. The non-pharmacological therapy segment is anticipated to be lucrative for market players, as these therapies cause fewer side effects as compared to drugs.

 

In 2016, North America accounted for the maximum contribution to the total revenue generated, owing to the high prevalence rate of insomnia, presence of high disposable income, and high demand for over-the-counter (OTC) drugs. In addition, the presence of large number of insomnia centers in this region and rise in the number of patients with chronic renal & kidney diseases are expected to boost the market growth. However, Asia-Pacific is expected to witness the highest CAGR during the study period, owing to increase in the number of people working at odd hours, rise in incidence rate of insomnia, and growth in disposable income.

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2373

 

Key Findings of the Insomnia Market:

• The cognitive behavioral therapy segment is anticipated to grow at the highest rate during the analysis period.
• The prescription drugs segment generated the highest revenue, and is expected to continue its dominance in the near future.
• North America dominated the global insomnia market, and is anticipated to continue its dominance in the future.
• China is expected to grow at highest CAGR in the Asia-Pacific.
• The pharmacological therapy segment was the largest contributor to the market growth, in 2016.

 

The key companies profiled in the report include Merck & Co. Inc., Sanofi India Limited, Pfizer, Inc., Takeda Pharmaceutical Company Ltd., Purdue Pharmaceuticals L.P., Eisai, Co. Ltd., Meda Consumer Healthcare Inc., Pernix Therapeutics, Vanda Pharmaceuticals, and ECR Pharmaceuticals.

 

Precision Medicine Market Is Expected to Reach $7,746 Million by 2023

 

Precision Medicine Market accounted for $3,516 million in 2016, and is estimated to reach at $7,746 million by 2023, registering a CAGR of 11.9% from 2017 to 2023. North America was the highest contributor in the precision medicine market in 2016; however, Asia-Pacific is anticipated to witness a highest growth rate throughout the forecast period.

 

Precision medicine is novel approach toward disease treatment in healthcare, medications are customized based on patients personalized healthcare needs such as, influence of genes & surrounding environment on patients health and result of various tests carried out on various levels. Follow-up on tests and treatment can be planned based on response of the patients toward treatment, which reduces side effects of drug and multiple administration of medications.

 

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/2311

 

 

The precision medicine market is expected to grow at a productive rate the during forecast period. Surge in global incidence of cancer and increase in aging population susceptible to diseases are expected to boost the demand of precision medicines. Government initiatives & grants and private companies investing in R&D of precision medicines boost the market growth. However, strict regulation set by governments and risk associated with sharing genetic data of patients impedes the growth of precision medicine market.

 

Drug discovery generated the highest revenue in 2016, and is anticipated to continue this trend in the future. The requirement of quality drugs and versatile therapies for treatment is expected to boost the growth of this segment. Gene sequencing grows at a surprising rate and is expected to continue to grow during the forecast period.

 

North America holds the highest market share in 2016 owing to high prevalence rate of cancer and modern healthcare facilities. Moreover, adoption of experimental medicines and growth in awareness about precision medicines is expected to boost the North America market. However, Asia-pacific region is expected to grow at the highest CAGR during the forecast period considering, swift industrialization in the area, increase in disposable income, and upsurge in government initiatives to modernize healthcare infrastructure.

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2311

 

Key Findings of the Precision Medicine Market:

• The sequencing by synthesis segment is projected to grow at the highest CAGR during the analysis period.
• Consumables segment generated the highest revenue and is expected to continue its dominance in future.
• North America dominated the market and is projected to grow at a CAGR of 11.0%.
• China is expected to grow at the highest CAGR of 16.8% in Asia-Pacific.
• The epigenomics segment is anticipated to grow at the highest CAGR of 14.1% during the forecast period.

 

The key companies profiled in the report include Roche Holding AG, Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN, Quest Diagnostics, Laboratory Corporation of America Holdings, Novartis AG, AstraZeneca, Bristol-Myers Squibb, and Eli Lilly & Company.

Potential Analysis of Human DNA Vaccines Market to Reach $9,337 Million by 2030

 

Potential Analysis of Human DNA Vaccines Market is expected to account for $3,762 million by 2020 and reach $9,337 million by 2030, growing at a CAGR of 9.5% from 2020 to 2030. Key opportunities for market expansion include the high need for vaccines for immunization & prevention of infectious diseases.

 

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/2309

 

Vaccines used currently are composed of killed pathogen or live attenuated viruses, whereas DNA vaccines consist of the DNA sequence of the antigen, which is administered in humans to stimulate an immune response. This approach offers a number of potential advantages over traditional approaches, including the stimulation of both B- and T-cell responses, improved vaccine stability, the absence of any infectious agent, and the relative ease of large-scale manufacture. In addition, DNA vaccines are temperature stable, leading to easier storage and transport. DNA vaccination may provide an important tool for stimulating an immune response in HBV, HCV, and HIV patients, owing to their therapeutic potential for ongoing chronic viral infection. For instance, Inovios INO-3112 is in phase II clinical trial, and can be used to treat cervical cancer caused by HPV. This immunotherapy enables the body to produce E6 and E7 antigens to induce a stronger targeted immune response against HPV-associated diseases, such as cervical cancer.

 

Key Findings of the Potential Analysis of Human DNA Vaccines Market:

• North America is expected to dominate the market in 2020, and is projected to grow at the highest CAGR during the forecast period.
• Europe is the second largest potential market, and is expected to grow at a CAGR of 9.0%.

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2309

 

The major players profiled in the global potential analysis of human DNA vaccines market are Inovio Pharmaceuticals, Inc., GeneOne Life Science Inc., MedImmune, Immunomic Therapeutics, Inc., Astellas Pharma, Inc., Pharos Biologicals, Sanofi S.A., F. Hoffmann-La Roche AG, CureVac, and Boehringer Ingelheim GmbH.

Blood Market Expected to Reach $10 Billion by 2027

According to a new report published by Allied Market Research, titled, "Blood Market by Product Type and End User:  Opportunity Analysis and Industry Forecast, 2019–2026," the global blood market was valued at $7 billion in 2019, and is expected to reach $10 billion by 2027, registering a CAGR of 4.5% from 2019 to 2027. 

 

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/2297

 

Blood is defined as the transport medium of the body responsible for carrying oxygen and nutrients to cells. Furthermore, blood is pumped by heart to all body parts, which is returned back to the heart by organs to complete the cycle. Hence, blood is vital for the human body as it is required for proper functioning of organs. However, various conditions such as traumatic injury and surgical procedures can lead to loss of blood form the body. In addition, certain medical conditions such as cancer, hemophilia, and kidney diseases also lead to lowering of blood cells in the body. Thus, these conditions require infusion of whole blood and other blood components to manage conditions in patients. Moreover, whole blood used in the treatment is collected through donations using blood collection systems and consumables. Similarly, plasma is collected using plasma collection systems and consumables. Furthermore, collected blood is subjected to other necessary procedures such as blood typing, which involves determining the blood type of the donated blood by using blood typing systems and reagents. In addition, blood is also subjected to screening to check the presence of infection markers.

 

Surge in demand for blood and plasma across the globe and rise in geriatric population worldwide are the major factors that boost the market growth. In addition, other factors such as increase in blood and plasma donations across the globe and favorable government regulations for blood screening. Furthermore, advancements in blood transfusion and blood screening instruments is another major factor that drives the growth of the blood blood market. 

However, factors such as high cost of advanced blood collection devices and lack of skilled laboratory professionals hinder the growth of the market. Conversely, developing economies offer lucrative growth opportunities for the market growth. 

 

The blood market is segmented into product, end user, and region. On the basis of product, it is classified into whole blood collection and processing, source plasma collection, blood typing products, and blood screening products. Furthermore, all these segments are further classified into sub-segments. For instance, the whole blood collection segment is classified into whole blood collection systems and whole blood collection consumables. The source plasma collection segment is classified into source plasma collection systems and source plasma collection consumables. In addition, the blood typing products are further bifurcated into blood typing systems, and blood typing reagents. The blood screening products are divided into blood screening systems and blood screening reagents. 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/2297

 

Key Findings of the Study 

·         By product, the whole blood collection and processing segment occupied more than half of the share of global blood market in 2020.

·         By end user, the blood and blood component bank segment is anticipated to grow with the highest CAGR throughout the forecast period.

·         By product, the source plasma collection segment is expected to grow with the highest CAGR during the forecast period. 

·         By region, Asia-Pacific is anticipated to grow at the highest rate during the analysis period. 

Gastroparesis Drugs Market to Reach $6,486 Million by 2023

 

According to a new report published by Allied Market Research, titled, Gastroparesis Drugs Market, by Drug Class, Disease Type, and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global gastroparesis drugs market was valued at $4,667 million in 2016, and is projected to reach $6,486 million at a CAGR of 4.7% from 2017 to 2023.

 

Click Here To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4153

 

Gastroparesis affects the normal spontaneous movement of the muscles of stomach and interferes with the normal digestion, thus causing nausea, vomiting, and problems related with blood sugar levels & nutrition. Gastroparesis is caused due to diabetes or can develop after surgery. Recently, advanced drugs such as metoclopramide, erythromycin, antiemetics, and others are developed to treat gastroparesis.

 

The major factors that drive the growth of the global gastroparesis drugs market are rise in number of surgeries that may lead to postoperative gastroparesis, increase in diabetic population, introduction of novel drugs, and surge in geriatric population. However, side effects associated with gastroparesis drugs and time-consuming regulatory approvals are expected to restrain the market growth. Conversely, huge untapped market potential in the emerging countries, such as China and India, and development of novel gastroparesis drugs are expected to provide lucrative opportunities to the market players.

 

The prokinetic agents segment occupied the largest share in 2016, owing to the high usage, applicability, and availability of prokinetic agents for treating gastroparesis. Furthermore, the botulinum toxin injection segment is expected to grow at the highest CAGR of 5.6% from 2017 to 2023, and is anticipated to continue its dominance during the forecast period. The utilization rate of gastroparesis drugs for idiopathic gastroparesis is high, however post-surgical gastroparesis segment is expected to grow at a CAGR of 5.2% during the forecast period. This is attributed to increase in incidence of various types of surgeries, such as transplantation, which result in postsurgical gastroparesis.

 

 

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4153

 

Key findings of the Gastroparesis Drugs Market:

• Prokinetic agents segment accounted for more than four-fifths share of the global gastroparesis drugs market in 2016.
• Botulinum toxin injection segment is expected to grow at a CAGR of 5.6% from 2017 to 2023.
• Idiopathic gastroparesis segment accounted for around 34.9% share of the global gastroparesis drugs market in 2016.
• Hospitals accounted for nearly two-fifths share of the global gastroparesis drugs market in 2016.
• Pharmacies segment is expected to grow at a CAGR of 5.0% from 2017 to 2023

 

North America was the leading revenue contributor to the global gastroparesis drugs market, accounting for nearly one-third of the global market. This is attributed to the early approval of gastroparesis drugs and high use of these drugs due to rise in incidence of gastroparesis. However, Asia-Pacific is expected to grow at the highest CAGR of 5.5% during the study period, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward gastroparesis drugs.

LAMEA IVD Market Expected to Reach $10,316 million by 2023

 According to a new report published by Allied Market Research, titled, LAMEA IVD Market by Product Type, Techniques, Application, and End Users: Opportunity Analysis and Industry Forecast, 2017-2023, the LAMEA IVD market was valued at $7,413 million in 2016, and is projected to reach at $10,316 million by 2023, growing at a CAGR of 4.7% from 2017 to 2023. The immunodiagnostics segment accounted for more than two-ninths share of the total market in 2016.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/4137

 

In vitro diagnostics (IVD) are medical devices and reagents used for examination of the body samples such as blood, tissue, and body fluids to detect diseases, disorders, and infections and identify suitable medical treatment. Rise in incidences of chronic and infectious diseases, constant technological developments to improve efficacy of IVD and increase in government healthcare expenditure in LAMEA region drive the market growth. However, stringent government regulations related to the safety and efficacy of the IVD and unfavorable reimbursement policies are expected to restrain the market growth during the forecast period. Ongoing R&D associated with the IVD and increased disposable income of consumers provides huge growth potential for IVD market.

Based on product type, the reagents segment held the highest market share in 2016, owing to the recent introduction of new novel reagents in the market that are more effective.
Based on technique, the immunodiagnostics segment contributed the highest market share in 2016, owing to the increase in prevalence of chronic and infectious diseases and rise in awareness of personalized medicine among the population.

Based on application, the infectious diseases segment contributed the highest market share in 2016, owing to the increase in prevalence of infectious diseases such as HIV, tuberculosis, and others.

Based on end users, the standalone laboratory segment captured the highest market share in 2016, mainly due to increase in outsourcing of diagnostic test by hospitals.

Latin America accounted for more than one-third share in 2016, and is expected to dominate the market throughout the forecast period and is attributed to increase in incidence of chronic and infectious diseases such as tuberculosis, diabetes, cancer, and others. In addition, lucrative growth opportunities in the economic emerging countries is anticipated to provide new growth opportunities for the key players in the market. However, Africa is estimated to register the highest growth rate during the forecast period, owing to rise in government healthcare expenditure and growth in demand for healthcare devices from large pool of patient population, and improvement in healthcare infrastructure.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4137

Key Findings of the LAMEA IVD Market:

• The reagents segment dominated the market in 2016, and is projected to grow at the 3.7% CAGR.
• The immunodiagnostics segment accounted for the highest share (one-eighth) in 2016.
• The infectious diseases segment was the major shareholder in the LAMEA IVD based application market in 2016.
• The standalone laboratory segment accounted for the highest share (two-ninths) in 2016.
• Latin America was the major shareholder of Asia Pacific IVD market in 2016.
• Africa is expected to grow at the highest CAGR in the LAMEA IVD market.

The major players profiled in the LAMEA IVD market are Thermo Fisher Scientific Inc., Alere Inc., Biomerieux, Danaher Corporation, F. Hoffmann-La Roche AG, Becton Dickinson and Company, Bio-Rad Laboratories, Bayer AG, Sysmex Corporation, and Johnson & Johnson among others.